Research of the mechanism of Chuanxiong Qingnao Granules in improving migraine based on network pharmacology and experimental validation
10.16438/j.0513-4870.2022-0860
- VernacularTitle:基于网络药理学探讨川芎清脑颗粒改善偏头痛作用机制及验证研究
- Author:
Jing-yi HOU
1
;
Li-qi NI
1
;
Liang-liang TIAN
2
;
He XU
2
;
Guang-zhao CAO
2
;
Kun WANG
1
;
Bo-wen HOU
1
;
Jing-jing ZHANG
2
;
Hong-jun YANG
1
Author Information
1. Beijing Key Laboratory of Traditional Chinese Medicine Basic Research on Prevention and Treatment for Major Diseases, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing 100700, China
2. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China
- Publication Type:Research Article
- Keywords:
Chuanxiong Qingnao Granules;
migraine headache;
network pharmacology;
biological mechanism;
ocking stimulation
- From:
Acta Pharmaceutica Sinica
2022;57(10):3095-3105
- CountryChina
- Language:Chinese
-
Abstract:
In this study, a research strategy integrating network pharmacology analysis and animal experimental validation was applied to explore the molecular mechanism of Chuanxiong Qingnao Granules (CXQN) in improving migraine headache (MH). All animal experiments were followed the regulation of the Laboratory Animal Ethics Committee of the China Academy of Chinese Medical Sciences. Based on the network pharmacology analysis, the 27 active ingredients and their corresponding 940 targets were obtained, and 99 common targets of CXQN in the treatment of MH were obtained by intersection, and tumor necrosis factor-α (TNF-α), interleukin (IL)-6, vascular endothelial growth factor A (VEGFA), IL-1β, brain-derived neurotrophic factor (BDNF) were screened out as hub targets. Enrichment analysis showed that the targets of CXQN in the treatment of MH were mainly involved in cyclic adenosine monophosphate (cAMP), hypoxia inducible factor-1 (HIF-1), phosphoinositide 3-kinase-protein kinase B (PI3K-Akt) signaling pathways. In addition, the experimental verification in the MH rat induced by nitroglycerin showed that the CXQN administrated groups could significantly improve the behavioral symptoms and regulate the level of vasoactive substances, and reduce the expression of TNF-α, IL-6, VEGFA, IL-1β, and BDNF at gene and protein levels. This study revealed the multi-component, multi-target, and multi-pathway characteristics of CXQN in the treatment of MH, and elucidated the potential mechanism of CXQN in the treatment of MH, laying a theoretical foundation and scientific basis for its clinical application in the treatment of MH diseases.
